Zoetis reported strong financial performance with significant growth in key product segments, particularly in companion animals and dermatology. Despite facing headwinds from foreign exchange and increased competition, the company remains confident in its ability to sustain above-market growth driven by innovation and strategic investments.

Company Guidance

During the Zoetis fourth quarter and full-year 2024 earnings call, the company reported robust performance metrics, achieving double-digit operational revenue growth of 11%, with the U.S. market seeing an 11% increase and international markets growing by 10% operationally. The companion animal portfolio led the way with 14% operational growth, while the livestock segment grew by 5% operationally. The Simparica franchise, a key driver, grew 28% operationally, and the osteoarthritis pain franchises, including Librela, saw an 80% operational increase. For 2025, Zoetis is guiding towards 6% to 8% organic operational revenue growth and adjusted net income growth, excluding interest and taxes, of 8% to 10%. The company remains confident in its ability to sustain above-market growth, driven by innovation, market expansion, and strategic investments in its portfolios, despite anticipated foreign exchange headwinds and competitive dynamics.

Record-Breaking Revenue and Growth

Zoetis reported $9.3 billion in revenue for 2024, growing 8% on a reported basis and 11% operationally. Adjusted net income grew 10% on a reported basis and 15% operationally to $2.7 billion.

Strong Performance in Companion Animal Portfolio

Companion animal portfolio grew 14% operationally. The Simparica franchise posted $1.4 billion in revenue, growing 28% operationally, and Librela and Solensia reported combined revenue of $581 million globally, growing 80% operationally.

Dermatology Franchise Growth

Dermatology franchise grew 17% operationally, generating $1.6 billion in revenue. Significant market expansion opportunities with 20 million untreated or undertreated dogs.

Livestock Portfolio Exceeds Expectations

Livestock portfolio delivered 5% operational revenue growth, exceeding initial expectations of 2% to 4% annual industry growth, with 7% growth on an organic operational basis.

Successful Product Launches

Librela's US launch became the most successful in Zoetis' history, reaching blockbuster status in less than four quarters.

---

Zoetis (ZTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 01, 2025	2025 (Q1)	1.41 / -	1.38	―	―	―
Feb 13, 2025	2024 (Q4)	1.36 / 1.40	1.24	12.90% (+0.16)
Nov 04, 2024	2024 (Q3)	1.46 / 1.58	1.36	16.18% (+0.22)
Aug 06, 2024	2024 (Q2)	1.49 / 1.56	1.41	10.64% (+0.15)
May 02, 2024	2024 (Q1)	1.35 / 1.38	1.31	5.34% (+0.07)
Feb 13, 2024	2023 (Q4)	1.32 / 1.24	1.15	7.83% (+0.09)
Nov 02, 2023	2023 (Q3)	1.36 / 1.36	1.21	12.40% (+0.15)
Aug 08, 2023	2023 (Q2)	1.31 / 1.41	1.2	17.50% (+0.21)
May 04, 2023	2023 (Q1)	1.25 / 1.31	1.32	-0.76% (-0.01)
Feb 14, 2023	2022 (Q4)	1.15 / 1.15	1	15.00% (+0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ZTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 13, 2025	$173.88	$164.93	-5.15%
Nov 04, 2024	$181.40	$174.65	-3.72%
Aug 06, 2024	$173.88	$184.29	+5.99%
May 02, 2024	$157.27	$165.94	+5.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---